---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-036448"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:25:34.095085+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jasper posts Q4 net loss $9.1M; cash $28.7M; appoints new CEO; reports positive CSU/asthma data

## Summary
- Jeet Mahal named President and CEO to lead next phase of clinical growth.
- Positive CSU data: 67% complete response in BEACON Cohort 9.1; 75% in open-label extension at 12 weeks.
- Preliminary asthma data from ETESIAN study shows reduced airway hyperresponsiveness after single 180mg dose.
- Internal investigation found no drug product issues; KOL panel recommends enhanced site selection and screening.
- Q4 2025 net loss $9.1M; year net loss $75.8M; cash and equivalents $28.7M at Dec 31, 2025.

## SEC filing metadata
- accession: 0001213900-26-036448
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026036448/0001213900-26-036448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026036448/ea0283364-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-036448
- JSON: https://secwatch.observer/filing/0001213900-26-036448.json
- Plain text: https://secwatch.observer/filing/0001213900-26-036448.txt

## Source-grounded claims
- claim_id: 973b93c97db069c18c98f94c676712c0debaafd3
  claim: Jasper Therapeutics, Inc. reported the quarter and year ended December 31, 2025 results: net income a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholder, EPS $0.32 and $3.95.
  evidence_excerpt: Jasper reported a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.32 and $3.95, for the three months and year ended December 31, 2025, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390026036448/0001213900-26-036448-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.